1. SMi Presents the 13th Annual 20 - 21
Pain Therapeutics M A Y
Copthorne Tara Hotel, London, UK 2013
WHY ATTEND THIS EVENT: FEATURED SPEAKERS:
• Balance of clinical and pre-clinical considerations • Dave Shelton, Executive Director Pfizer
,
alongside therapeutic applications • Narender Gavva, Scientific Director Amgen
,
• Focus on personalised medicine and translational • Stephen Arneric, Senior Research Fellow, Eli Lilly
methods aiming to develop the efficacy of drugs • Thomas Christoph, Global Preclinical Research and
• Explore the use of anti-NGFs in the treatment of Development, Grunenthal
pain alongside the discovery of novel targets • Huw Rees, Senior Principal Scientist, Pfizer
• Spotlight on translational mechanistic pain • Steve Harrison, Vice President, Research Biology,
biomarkers Nektar Therapeutics
• Study the use of imaging modalities such as fMRI • Iain Chessell, Head, Neuroscience Centre of Excellence,
for pain measurement MedImmune
• Network with key industry professionals and • Valerie Morisset, Head of Electrophysiology,
discuss the future of pain therapeutics Convergence Pharmaceuticals
PLUS TWO INTERACTIVE POST-CONFERENCE WORKSHOPS
22ND MAY 2013 | COPTHORNE TARA HOTEL | LONDON, UK
Workshop A: Workshop B:
Human Pain Models - Lost in Translation? Using phenotyping and imaging to improve early
08.30 – 12.30 drug development and clinical trial design
Workshop Leaders: Jonathan Stewart, Consultant, Pain Medicine, 13.30 – 17.30
Imperial NHS Trust, London Workshop Leader: Anthony Jones, Professor of
Zahid Ali, Senior Director, Pfizer Neuro-rheumatology, University of Manchester
Remigiusz Lecybyl, Consultant in Chronic Pain,
Lewisham Hospital
To attend, contact Cem Tuna on Tel +44 (0) 20 7827 6736,
Fax +44 (0) 20 7827 6737, email ctuna@smi-online.co.uk
or visit www.smi-online.co.uk/ts07.asp to register online

2. DAY ONE | 20TH MAY 2013 Pain Therapeutics
08.30 REGISTRATION & COFFEE 12.10 Chronic pain treatments tailored for the elderly: are we
prepared for the approaching tsunami?
• Chronic pain is becoming increasingly recognized as a disease -
09.00 CHAIRMAN’S OPENING REMARKS: accounts for substantial suffering and disability world-wide
Dave Shelton, Executive Director, Pfizer • The aging “Baby-boomer” generation
• The phenotypic expression of chronic pain in the elderly
• A paradigm shift in the drug discovery paradigm
PERSONALISED MEDICINE & ANIMAL MODELS Stephen Arneric, Senior Research Fellow, Eli Lilly
12.50 NETWORKING LUNCH
09.10 The use of ddRNA interference as a gene therapy
approach to cancer pain management CURRENT & NOVEL TARGETS
• Inflammation and epigenetics - developing treatments
• Understanding the epigenome - combination therapy 14.10 The use of anti-NGF agents in pain
• Application of epigenetics to answer questions about • Novel approach to treating pain
established drugs • anti-NGF in clinical trials
Peter French, Chief Executive Officer, Benitec Biopharma • Challenges faced
• Future of anti-NGF agents
Dave Shelton, Executive Director, Pfizer
09.50 Novel readouts for the analysis of spontaneous pain
in animals 14.50 Novel pain therapeutics with low CNS side effects
• How do evoked methods compare with non-evoked? • Use of polymer conjugation technology to develop novel
• Are innate responses of animals suitable measures for opioids with intrinsically low abuse liability
chronic pain? • Analgesics for neuropathic pain with reduced CNS side effects
• Are different pain indications amenable to similar readouts? • The future potential of polymer conjugation technology in
Thomas Christoph, Global Preclinical Research and pain therapy
Development, Grunenthal Steve Harrison, Vice President, Research Biology, Nektar
Pharmaceuticals
10.30 Optimising the context of medical treatments for 15.30 AFTERNOON TEA
arthritis pain
• The context within which treatments are given 15.50 Novel targets in inflammatory and neuropathic pain
• Placebos and nocebo • Inflammatory and neuropathic pain poorly treated by
• The place of medical analgesia in patient pathways for current analgesics – poor efficacy and many side effects
chronic arthritis pain. • Recent work in the McNaughton lab has identified the HCN2
• The person-specific context; mechanistic, diagnostic and ion channel and the AKAP79 scaffolding protein as potential
targets
severity-based approaches to stratified care
• Progress towards developing selective drugs
David Walsh, Director of the ARC National Pain Centre,
Peter McNaughton, Head of Pharmacology Department,
University of Nottingham Cambridge University
11.10 MORNING COFFEE 16.30 The use of biologic therapies in the treatment of pain -
A CASE STUDY of anti-NGFs
11.30 Exploring the use of animal models to study pain pathways • Why consider biologic therapies for pain: pros and cons
• Mechanistic studies; examining the role of NaV1.7 in rats • Considerations around target selection
• Case study: anti-NGF therapies
and mice
• Translation from man to animal to man
• Addressing bias in preclinical studies; being more clinical in
• Next steps for novel biologic therapies
experimental design Iain Chessell, VP R&D, Neuroscience Innovative Medicines,
• Future directions; re-evaluating the role of wide dynamic MedImmune
range neurones in models of nerve injury
Huw Rees, Senior Principal Scientist, Pfizer 17.10 Chairman’s Closing Remarks and Close of Day One
To attend, contact Cem Tuna on Tel +44 (0) 20 7827 6736, Fax +44 (0) 20 7827 6737
email ctuna@smi-online.co.uk or visit www.smi-online.co.uk/ts07.asp to register online
WHO SHOULD ATTEND: Want to know how you
Heads of Department, Directors, Managers, can get involved?
Interested in promoting
Team Leaders Researchers and Scientists from: your pharmaceutical
• Pain and inflammation target discovery • Chronic and neuropathic pain services to this market?
• Analgesic preclinical development • Clinical trial design Contact Margaret Mugema,
• CNS clinical trials • Biomarker development SMi Marketing on
• Translational imaging • Personalised medicine +44 (0) 207 827 6072,
• Early phase CNS research • Pain management or email
• Epigenetics in pain and inflammation mmugema@smi-online.co.uk
Supported by

3. DAY TWO | 21ST MAY 2013 Pain Therapeutics
08.30 REGISTRATION & COFFEE CLINICAL TRIAL MODELS & OVERCOMING CHALLENGES
11.40 Challenges in analgesic drug discovery
09.00 CHAIRMAN’S OPENING REMARKS:
• Emphasis is on preclinical discovery
Narender Gavva, Scientific Director, Amgen
• Potential false-positive hotspots
• Best practices for target selection criteria
EXPERIMENTAL MODELS Narender Gavva, Scientific Director, Amgen
09.10 Translational mechanistic pain biomarkers 12.20 NETWORKING LUNCH
• Phase I and II proof-of-concept
13.40 PFIZER SESSION – Current considerations in sodium
• Pharmacodynamics &Mechanism based drug profiling
channel blockers for pain management
• Healthy volunteer studies Session 1: The discovery and preclinical development
• Proof-of-mechanism of selective sodium channel blockers
• Translation of animal data into pain patients • Strategies for gaining true selectivity in sodium channel
Lars Arendt-Nielsen, Director, Center for Sensory-Motor blockers
• Preclinical in vitro and in vivo profile of selective Nav 1.7
Interaction, Aalborg University
blockers
• Key criteria in clinical compound selection
09.50 Human tissues as a translational tool in pain research Richard Butt, Director, Research Project Leader, Pfizer
and target identification
• Studies of neuropathic pain Session 2: Subtype selective sodium channel blockers
• Studies of inflammatory pain • Functional properties
• Novel classes of blockers
• Correlation with pre-clinical models
• The future of subtype selective sodium channel blockers
Fiona Boissonade, Head of Neuroscience Research Group,
Zahid Ali, Senior Director, Pfizer
University Of Sheffield
15.00 Afternoon Tea
10.30 MORNING COFFEE
15.30 CASE STUDY: Focus on Nav1.7 blockers for chronic pain
• Preclinical and clinical programmes at Convergence
11.00 Imaging the common brain substrates of chronic pain-
Pharmaceuticals
it’s all anticipation
• Nav1.7 blockers - research findings and major conclusions
• Recent research to suggest that fundamental changes in • The future of Nav1.7 blockers for chronic pain
physiology of chronic pain sufferers may alter their PD Valerie Morisset, Head of Electrophysiology, Convergence
compared to experimental models of healthy patients Pharmaceuticals
• Can this research help to illuminate better ways at predicting
16.10 Panel discussion : Pain therapeutics, where are we and
drug PD in patients?
what is the potential for the future?
• How do these physiological changes relate to pain?
Panellists: Day 2 Speakers
Anthony Kenneth Peter Jones, Professor of Neuro-
Rheumatology, University of Manchester 16.50 Chairman’s Closing Remarks and Close of Day Two
To attend, contact Cem Tuna on Tel +44 (0) 20 7827 6736, Fax +44 (0) 20 7827 6737
email ctuna@smi-online.co.uk or visit www.smi-online.co.uk/ts07.asp to register online
SMi PHARMACEUTICALS FORWARD PLANNER 2013
FEBRUARY Imaging in Cancer Drug Pharmaceutical JUNE SPONSORSHIP AND
Development Portfolio & Lifecycle
Parallel Trade
13 – 14 March 2013, Management
RNAi & Nanotechnology EXHIBITION OPPORTUNITIES
6 – 7 February 2013, 5 – 6 June 2013, London
London 17 – 18 April 2013,
London
London SMi offer sponsorship,
Biobanking
Controlled Release
Advances and Progress
18 – 19 March 2013, MAY
24-25 June 2013, London exhibition, advertising and
in Drug Design branding packages, uniquely
London
18 – 19 February 2013, Generics, Supergenerics Allergies
London & Patent Strategies 26 – 27 June 2013, tailored to complement your
Paediatric Clinical Trials
13 – 14 May 2013, London London company's marketing strategy.
20 – 21 March 2013,
Lyophilisation
London Should you wish to join the
- Freeze Drying in Pain Therapeutics ADMET
Pharmaceuticals 20 – 21 May 2013, London 26 – 27 June 2013, increasing number of
APRIL
and Biopharmaceuticals London
companies benefiting from
25 – 26 February 2013, Adaptive Designs ADC Summit
London 8 – 9 April 2013, London 20 – 21 May 2013, London JULY sponsoring our conferences
Pharmacovigilance please call:
MARCH Asthma & COPD Clinical Trial Logistics
1 – 2 July 2013, London Anuja Raut, SMi Sponsorship
15 – 16 April 2013, 22 – 23 May 2013, London
Superbugs &
London on +44 20 7827 6128 or
Superdrugs - A Focus Cell Culture
on Antibacterials 3 – 4 July 2013, London email: araut@smi-online.co.uk
4 – 5 March 2013, London

4. INTERACTIVE POST CONFERENCE
WORKSHOP A
22ND MAY 2013
Human Pain Models - Lost in Translation?
08.30 – 12.30
Workshop Leaders: Jonathan Stewart,
Consultant, Pain Medicine, Imperial NHS
Trust, London
Zahid Ali, Senior Director, Pfizer
Remigiusz Lecybyl, Consultant in Chronic
Pain, Lewisham Hospital
Overview
This workshop will be a uniquely interactive
session where attendees can explore currently
used human pain models and their
translatability into the clinic. Led by the
experience of Jonathan Stewart, Imperial
NHS Trust, London alongside the expertise of
Zahid Ali, Pfizer and Remigiusz Lecybyl,
Lewisham Hospital, the workshop aims to
facilitate the understanding of unmet needs in
human pain modeling and successful translation
to the clinic.
Benefits of Attending
• Address and overcome challenges
associated with human pain models
• Debate the attributes of currently used
human pain models
• Learn how successful models translate
• Network with key professionals with
considerable expertise in pain research
Agenda
08.30 Registration & Coffee
09.00 Introduction and Workshop Objectives
09.10 Attributes of currently used models
and which is best
• Comparative models
• Which model comes out on top
09.45 Do experimental models really
serve the function that they are
intended for?
• Functionality of human pain models
• Major findings
10.45 Morning Break
11.00 How well do these experimental
models translate?
• Translation into the clinic
12.10 Interactive Discussion
12.30 Summary & close of workshop
About Workshop Host:
Dr Jonathan Stewart is an anaesthetist with
almost 20 years clinical and research
experience in pain. He has undertaken
Consultant positions in pain
management at Kings College, St
Mary's Hospital and Charing Cross Hospital,
London as well as having an Honorary Senior
Lecturer appointment at Imperial College,
London.
Dr Stewart's interests are in neuropathic pain,
chronic spinal pain, musculoskeletal pain and
fibromyalgia. He has led research teams in all
these areas, been an invited speaker at national
and international conferences and advised the
UK government as an invitee on the Chronic
Pain Policy Coalition.

5. INTERACTIVE POST CONFERENCE
WORKSHOP B
22ND MAY 2013
Using phenotyping and imaging to
improve early drug development and
clinical trial design
13.30 – 17.30
Workshop Leader: Anthony Jones,
Professor of Neuro-rheumatology,
University of Manchester
Overview
This workshop will be a uniquely interactive session
where attendees can address and evaluate the use
of phenotyping and imaging modalities to improve
the success of early drug development and clinical
trial design. Led by the expertise of Anthony
Jones, Professor of Neuro-rheumatology,
University of Manchester, this workshop aims to
provide attendees with an exclusive insight into
successful methods that have improved drug
development in pain, alongside discussing the
future of pain therapeutics.
Benefits of Attending
• Address and overcome challenges
associated with drug development in pain
alongside clinical trial design
• Discuss advances in patient phenotyping
and ways to move forward with one's own
research
• Evaluate successful imaging modalities for
early drug development
• Network with key professionals with
considerable expertise in pain research
Agenda
13.30 Registration & Coffee
14.00 Introduction and Workshop Objectives
14.10 Using imaging modalities in drug
design
• Recent PET studies
• Successful imaging modalities
14.45 Application of patient phenotyping
• Drug development via phenotyping
• Patient phenotyping and clinical trial
design
15.45 Morning Break
16.00 Early drug development and clinical
trial design
• Current applications of phenotyping
alongside imaging
• Major findings and conclusions
17.10 Interactive Discussion
17.30 Summary & close of workshop
About Workshop Host:
Anthony Jones is professor of Neuro-
rheumatology at Manchester University and
leads the Human Pain Research Group. Whilst at
the Hammersmith Hospital he pioneered the
development of techniques to image
neurochemical and metabolic brain responses to
pain using Positron Emission Tomography. Over
SPONSORSHIP AND
the last twenty years he has used a number of
functional brain imaging techniques to
EXHIBITION
understand that the normal and abnormal
mechanismsOPPORTUNITIES
of pain perception.
There is offer the exciting prospect of using
SMi now sponsorship, exhibition,
some of the insights gained in these studies to
advertising and branding packages,
develop new approaches to complement
uniquely tailored to pharmacological
and cognitive interventions for chronic pain. He
your company's marketing strategy.
also leads the International Association of Pain
Musculoskletal Pain Taskforce to join the the
Should you wish and is leading
development of number of companies
increasing National and International
Guidelines on the from sponsoring our of
benefiting Integrated Management
Musculoskeletal Pain (jointly sponsored by the
conferences please call: Anuja Raut,
BSR and the IASP).
SMi Sponsorship on +44 20 7827
6128

6. PAIN THERAPEUTICS
Conference: Monday 20th and Tuesday 21th May 2013, Copthorne Tara Hotel, London, UK Workshops: Wednesday 22nd May 2013, London
4 WAYS TO REGISTER
ONLINE at www.smi-online.co.uk/ts07.asp
FAX your booking form to +44 (0) 20 7827 6737 POST your booking form to: Cem Tuna, SMi Group Ltd, 2nd Floor South,
PHONE on +44 (0) 20 7827 6736 Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
EARLY BIRD □ Book by 28th February to receive a £300 off the conference price
DISCOUNT □ Book by 28th March to receive a £100 off the conference price
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & 2 Workshops £2697.00 + VAT £3236.40
□ Conference & 1 Workshop £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
Unique Reference Number □ 1 Workshop only £599.00 + VAT £718.80
Our Reference LVP-067 ts □ 2 Workshops £1198.00 + VAT £1437.60
Workshop A □ Workshop B □
DELEGATE DETAILS
PROMOTIONAL LITERATURE DISTRIBUTION
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
□ Distribution of your company’s promotional
Title: Forename:
literature to all conference attendees £999.00 + VAT £1198.80
Surname:
Job Title: The conference fee includes refreshments, lunch, conference papers and access
Department/Division: to the Document Portal containing all of the presentations.
Company/Organisation:
Email:
VENUE Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SR
Company VAT Number:
Address:
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
Town/City:
Post/Zip Code: Country: DOCUMENTATION
Direct Tel: Direct Fax:
I cannot attend but would like to purchase access to the following Document
Mobile: Portal/paper copy documentation Price Total
Switchboard: □ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
Signature: Date: □ The Conference Presentations – paper copy £499.00 - £499.00
I agree to be bound by SMi's Terms and Conditions of Booking. (or only £300 if ordered with the Document Portal)
ACCOUNTS DEPT
Title: Forename: PAYMENT
Surname: Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-067 and the delegate’s name. Bookings
Email: made within 7 days of the event require payment on booking, methods of payment
Address (if different from above): are below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Town/City: Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
Post/Zip Code: Country:
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
Direct Tel: Direct Fax: □ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Terms and Conditions of Booking Card No: □□□□ □□□□ □□□□ □□□□
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may Cardholder’s Name:
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a Signature: Date:
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing I agree to be bound by SMi's Terms and Conditions of Booking.
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable Card Billing Address (If different from above):
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other VAT
products and services. Unless you tick here □ we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document
that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or
visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on Portal and Literature Distribution for all UK customers and for those EU customers not supplying
the attached letter. a registration number for their own country here: ______________________________________
If you have NOT received registration confirmation within 48 hours of registering, please call +44 (0) 20 7827 6736